Comparing of Clearside Biomedical Inc. (CLSD) and Gossamer Bio Inc. (NASDAQ:GOSS)

Clearside Biomedical Inc. (NASDAQ:CLSD) and Gossamer Bio Inc. (NASDAQ:GOSS) compete with each other in the Biotechnology sector. We will analyze and compare their dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Clearside Biomedical Inc. N/A 815.16 77.67M -2.66 0.00
Gossamer Bio Inc. N/A 0.00 114.62M -1.81 0.00

Table 1 shows gross revenue, earnings per share and valuation of the two companies.


Table 2 shows the net margins, return on equity and return on assets of the two firms.

Net Margins Return on Equity Return on Assets
Clearside Biomedical Inc. 0.00% -142.5% -102.8%
Gossamer Bio Inc. 0.00% 0% 0%


Clearside Biomedical Inc.?s Current Ratio and Quick Ratio are 4.6 and 4.6 respectively. The Current Ratio and Quick Ratio of its competitor Gossamer Bio Inc. are 17.3 and 17.3 respectively. Gossamer Bio Inc. therefore has a better chance of paying off short and long-term obligations compared to Clearside Biomedical Inc.

Institutional & Insider Ownership

Institutional investors owned 56% of Clearside Biomedical Inc. shares and 31.6% of Gossamer Bio Inc. shares. Clearside Biomedical Inc.’s share owned by insiders are 13.31%. Comparatively, insiders own roughly 1.1% of Gossamer Bio Inc.?s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Clearside Biomedical Inc. -9.09% 18.64% -11.95% -78.63% -80.09% 30.84%
Gossamer Bio Inc. -1.47% 0% 0% 0% 0% 27.26%

For the past year Clearside Biomedical Inc. was more bullish than Gossamer Bio Inc.


Gossamer Bio Inc. beats Clearside Biomedical Inc. on 4 of the 7 factors.

Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops first-in-class drug therapies to treat blinding diseases of the eye. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion (RVO); and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase I/II clinical trial for diabetic macular edema (DME). The company’s pre-clinical development program for axitinib for the treatment of wet age-related macular degeneration (wet AMD). Clearside Biomedical, Inc. has a collaboration agreement with Santen Pharmaceutical Co., Ltd. to develop compounds for suprachoroidal space injection that are designed to treat DME, wet AMD, and RVO, as well as to reduce elevated intraocular pressure associated with glaucoma for a sustained period of time. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.